Picture of Charles River Laboratories International logo

CRL — Charles River Laboratories International Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapNeutral

Momentum

Relative Strength (%)
1m-11.18%
3m-22.06%
6m-28.89%
1yr-23.8%
Volume Change (%)
10d/3m+35.15%
Price vs... (%)
52w High-48.76%
50d MA-12.32%
200d MA-33.36%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)19.16
PEG Ratio (f)0.8
EPS Growth (f)31.28%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value4.59
Price to Tang. Bookn/a
Price to Free Cashflow29.08
Price to Sales3.3
EV to EBITDA15.79

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital10.49%
Return on Equity17.88%
Operating Margin17.57%

Financial Summary

Year End 25th DecUnit201720182019202020212022E2023ECAGR / Avg
Total Revenue$m1,857.62,266.12,621.232,923.933,540.164,046.244,496.6516.06%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+14.26+14.28+16.47+33.54+4.58+45.7+15.38n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for CRL

What can we use to predict NYQ:CRL's share price direction? background image

What can we use to predict NYQ:CRL's share price direction?

An important question for large-cap investors right now is whether the current market uncertainty caused by Covid-19 will affect the share prices of companies like Charles River Laboratories International Inc. Charles River Laboratorie...

What can we use to predict NYQ:CRL's share price direction? background image

What can we use to predict NYQ:CRL's share price direction?

An important question for large-cap investors right now is whether the current market uncertainty caused by Covid-19 will affect the share prices of companies like Charles River Laboratories International Inc. Charles River Laboratorie...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
25th Dec 202225th Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Charles River Laboratories International EPS forecast chart

Profile Summary

Charles River Laboratories International, Inc. is a full service, non-clinical contract research company. The Company provides research models required in research and development of new drugs, devices, and therapies. The Company's segments include Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the research models, research model services, and research and GMP-compliant cells businesses. The DSA segment includes services required to take a drug through the early development process, including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions (Biologics), and Avian Vaccine Services (Avian).

Directors

Last Annual
December 25th, 2021
Last Interim
March 26th, 2022
Incorporated
February 3rd, 1994
Public Since
June 23rd, 2000
No. of Shareholders
78
No. of Employees
18,600
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNew York Stock Exchange
Shares in Issue
50,804,860

CRL Share Price Performance

Upcoming Events for CRL

Q2 2022 Charles River Laboratories International Inc Earnings Release

Q3 2022 Charles River Laboratories International Inc Earnings Release

Similar to CRL

Picture of ADC Therapeutics SA logo

ADC Therapeutics SA

us flag iconNew York Stock Exchange

Ambrx Biopharma

us flag iconNew York Stock Exchange

Picture of Annovis Bio logo

Annovis Bio

us flag iconNew York Stock Exchange

Picture of Arcus Biosciences logo

Arcus Biosciences

us flag iconNew York Stock Exchange

Picture of Biohaven Pharmaceutical Holding logo

Biohaven Pharmaceutical Holding

us flag iconNew York Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email